Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Tibet Rhodiola Pharmaceutical Holding Co
Total Assets
Tibet Rhodiola Pharmaceutical Holding Co
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Tibet Rhodiola Pharmaceutical Holding Co
SSE:600211
|
Total Assets
¥6.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
16%
|
CAGR 10-Years
24%
|
|
|
Sinopharm Group Co Ltd
HKEX:1099
|
Total Assets
¥390.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
11%
|
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Total Assets
¥233.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Total Assets
¥112.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Total Assets
¥36.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
19%
|
|
|
Huadong Medicine Co Ltd
SZSE:000963
|
Total Assets
¥39.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
Tibet Rhodiola Pharmaceutical Holding Co
Glance View
Tibet Rhodiola Pharmaceutical Holding Co., nestled in the sprawling and mystical landscape of Tibet, is a beacon of traditional Chinese medicine intertwined with contemporary pharmaceutical practices. The company's genesis lies in the rich, indigenous knowledge of the Rhodiola plant, revered for its supposed adaptogenic properties, which potentially aid in combating stress and fatigue. The plant flourishes in the harsh, high-altitude environment of the Tibetan Plateau, and Tibet Rhodiola has adeptly harnessed both its historical and geographical advantages to cultivate, extract, and process Rhodiola into various health products. These formulations, which range from dietary supplements to wellness solutions, reflect a marriage of ancient herbal wisdom with modern scientific methodologies. Central to the company's business model is its vertically integrated supply chain, which allows it to oversee and control every aspect of production—from the sustainable harvesting of Rhodiola to its research and development ventures. This integration not only ensures quality and efficacy but also fortifies the company's brand as a trustworthy entity within the competitive herbal supplements market. By expanding its distribution channels, Tibet Rhodiola has successfully entered both domestic and international markets, leveraging the rising global enthusiasm for natural and holistic healthcare solutions. This strategic movement feeds directly into its revenue system, which thrives on the growing demand for health products that claim to support vitality and resilience, mirroring the age-old allure of Tibetan medicinal practices.
See Also
What is Tibet Rhodiola Pharmaceutical Holding Co's Total Assets?
Total Assets
6.3B
CNY
Based on the financial report for Dec 31, 2025, Tibet Rhodiola Pharmaceutical Holding Co's Total Assets amounts to 6.3B CNY.
What is Tibet Rhodiola Pharmaceutical Holding Co's Total Assets growth rate?
Total Assets CAGR 10Y
24%
Over the last year, the Total Assets growth was 32%. The average annual Total Assets growth rates for Tibet Rhodiola Pharmaceutical Holding Co have been 15% over the past three years , 16% over the past five years , and 24% over the past ten years .